Many countries with national health care systems or payers such as insurance companies use cost-effectiveness analyses to decide whether to cover new medicines, balancing treatment costs with potential health benefits.
May 30, 2024
0
7
For patients with systemic lupus erythematosus (SLE), iberdomide at a higher dose is superior to placebo for the rate of response indicating reduction in disease activity, according to a study published in the March 17 issue ...
Mar 17, 2022
0
15
As compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer (NSCLC), the biomarker-driven Lung Cancer Master Protocol (Lung-MAP) has enrolled higher percentages of patients who are older, ...
Sep 7, 2023
0
1
Imaging the tumors of patients with advanced melanoma receiving pembrolizumab (Keytruda) after only one week—rather than the standard of around three months—identified metabolic changes that corresponded with treatment ...
Jan 24, 2024
0
0
An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab, a monoclonal antibody that targets the protein receptor CTLA-4, to a regimen with the checkpoint inhibitor nivolumab could improve ...
Sep 19, 2018
0
1
The U.S. Food and Drug Administration has told drugmakers to add a boxed warning to a type of cancer treatment called CAR-T therapy, saying the treatment itself may sometimes cause a secondary cancer.
Jan 24, 2024
0
6
Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastatic breast cancer previously treated ...
Dec 7, 2022
0
4
Pharmaceutical giant Eli Lilly announced Monday it will acquire Loxo Oncology for around $8 billion, the latest big transaction aimed at developing and monetizing new treatments for cancer.
Jan 7, 2019
0
0
Determining the optimal treatment sequence for patients with BRAF V600 mutant metastatic melanoma was the focus of the DREAMseq phase 3 clinical trial. The combination of nivolumab and ipilimumab (N/I), followed by the combination ...
Nov 16, 2021
0
1
Expanded U.S. Preventive Services Task Force (USPSTF) criteria for lung cancer screening (LCS) in 2021 have resulted in a 65.9 percent increase in the number of eligible individuals, according to a research letter published ...
Mar 22, 2024
0
0
